Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia.

Elena Inzoli,Elena Crisà,Novella Pugliese,Ivan Civettini,Giuseppe Lanzarone,Andrea Castelli,Vincenzo Martinelli,Laura Montelisciani,Laura Antolini,Carlo Gambacorti-Passerini,Elena Maria Elli

European journal of haematology（2023）

引用 0|浏览21

暂无评分

摘要

B-ESA seems to be an effective and well-tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation.

查看译文

关键词

Janus kinase inhibitors,anemia,biosimilar pharmaceuticals,erythropoiesis-stimulating agents,myelofibrosis,outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要